BerGenBio ASA (BRRGF)

0,0250 0,0000 (0,00%) Börsenschluss: 03:32PM EDT

BerGenBio ASA

Møllendalsbakken 9
Bergen 5009
Norway
47 55 96 11 59
https://www.bergenbio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 18

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Martin Olin	Chief Executive Officer	860,75k	N/A	1969
Mr. Rune Skeie	Chief Financial Officer	232,89k	N/A	1973
Ms. Gayle M. Mills M.B.A	Chief Business Officer	N/A	N/A	1955
Ms. Cristina Oliva M.D.	Chief Medical Officer	31,17k	N/A	N/A
Graham Morell	Head of IR	N/A	N/A	N/A
Dr. Akil Jackson	Medical Director	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Corporate Governance

BerGenBio ASAs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.